(ELTX)
0.00
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
0.00
0.00 (0.00%)
Elicio Therapeutics, Inc., klinik bosqichdagi biotexnologiya kompaniyasi, saratonni davolash uchun immunoterapiyalarni ishlab chiqadi. Uning asosiy mahsulot nomzodi, ELI-002, yettita Kirsten rat sarcoma viral oncogene homolog (Kirsten sichqoncha sarkomasi virusli onkogeni homolog) haydovchi mutatsiyalari uchun II bosqich klinik sinovlarida bo'lgan ko'p valentli limfa tugunlariga yo'naltirilgan amfifil (AMP) peptid vaktsinasidir. Kompaniya, shuningdek, mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) tomonidan qo'zg'atilgan saraton kasalliklari uchun ko'p valentli limfa tugunlariga yo'naltirilgan ELI-007 va mutatsiyaga uchragan o'simta proteini p53ni ifodalovchi saraton kasalliklarini davolash uchun preklinik tadqiqotlarda bo'lgan ko'p valentli limfa tugunlariga yo'naltirilgan ELI-008ni ishlab chiqadi. Elicio Therapeutics, Inc. shtab-kvartirasi Boston, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Allen Richard Nissenson F.A.S.N., FACP, M.D. | Founder & Independent Director |
| Dr. Christopher M. Haqq M.D., Ph.D. | Executive VP, Head of Research & Development and Chief Medical Officer |
| Dr. Darrell J. Irvine Ph.D. | Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board |
| Dr. Peter DeMuth Ph.D. | Chief Scientific Officer |
| Dr. Preetam Shah M.B.A., Ph.D. | Chief Strategy & Financial Officer and Treasurer |
| Mr. Marc J. Wolfgang M.S. | Chief Technology Officer |
| Mr. Robert T. Connelly |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-16 | 8-K | angn-20260316.htm |
| 2026-03-12 | S-8 | elicios-8march2026.htm |
| 2025-11-13 | S-3 | elicio-resalesx3.htm |
| 2025-09-17 | 8-K | d38971d8k.htm |
| 2025-08-12 | 8-K | angn-20250812.htm |
| 2025-08-07 | 8-K | angn-20250807.htm |
| 2025-08-05 | 8-K | angn-20250805.htm |
| 2025-06-04 | 8-K | angn-20250604.htm |
| 2025-05-20 | 8-K | angn-20250519.htm |
| 2025-05-13 | 10-Q | angn-20250331.htm |
| CEO, President & Director |
| Ms. Esther Welkowsky | Senior Vice President of Clinical Development |
| Ms. Joy Seymour | VP & Head of Regulatory Affairs |
| Ms. Megan C. Filoon | General Counsel, Secretary & Compliance Officer |